RARE
$41.4
Revenue | $139.29Mn |
Net Profits | $-151.08Mn |
Net Profit Margins | -108.46% |
Ultragenyx Pharmaceutical Inc.’s revenue jumped 27.99% since last year same period to $139.29Mn in the Q1 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -15.52% fall in its revenue since last 3-months.
Ultragenyx Pharmaceutical Inc.’s net profit jumped 11.49% since last year same period to $-151.08Mn in the Q1 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -13.27% fall in its net profits since last 3-months.
Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 30.84% since last year same period to -108.46% in the Q1 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -34.07% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -1.29 |
EPS Estimate Current Year | -1.29 |
Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.29 - a -0.78% fall from last quarter’s estimates.
Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.29.
Earning Per Share (EPS) | 0 |
Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-11-04 | -1.29 | 0 | 100% |
2025-05-07 | -1.75 | -1.57 | 10.29% |
2025-07-31 | -1.28 | 0 | 100% |